deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT05250063

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) (OraGrowtH213)

A Multicenter, Open-Label, Phase 2 Study to Evaluate Growth and Safety of LUM-201 Following 12 Months of Daily rhGH Treatment in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed the LUM-201-01 Trial

Sponsor: Lumos Pharma

Conditions Growth Hormone Deficiency
Interventions LUM-201
Updated 15 times since 2022 Last updated: Sep 24, 2025 Started: Feb 18, 2022 Primary completion: Jan 22, 2025 Completion: Jan 22, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Growth Hormone Deficiency and is currently completed. Lumos Pharma leads this study, which shows 15 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Nov 2023 · 5 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

15 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Enrolling By Invitation → Active Not Recruiting

▶ Show 10 earlier versions

  1. Feb 2024 — Mar 2024 [monthly]

    Enrolling By Invitation PHASE2

  2. Dec 2023 — Feb 2024 [monthly]

    Enrolling By Invitation PHASE2

  3. Nov 2023 — Dec 2023 [monthly]

    Enrolling By Invitation PHASE2

  4. Jun 2023 — Nov 2023 [monthly]

    Enrolling By Invitation PHASE2

  5. May 2023 — Jun 2023 [monthly]

    Enrolling By Invitation PHASE2

  6. Apr 2023 — May 2023 [monthly]

    Enrolling By Invitation PHASE2

  7. Feb 2023 — Apr 2023 [monthly]

    Enrolling By Invitation PHASE2

  8. Sep 2022 — Feb 2023 [monthly]

    Enrolling By Invitation PHASE2

  9. Apr 2022 — Sep 2022 [monthly]

    Enrolling By Invitation PHASE2

    Status: Not Yet Recruiting → Enrolling By Invitation

  10. Mar 2022 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Lumos Pharma
Data source: Lumos Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations